Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

SAFE-T Consortium under the EU Innovative Medicines Initiative (IMI) – First Year of Active Collaboration

16.06.2010
Faster Development of Safer Medicines through Translational Safety Biomarkers

The SAFE-T Consortium has been working together for a year now. The project addresses the current lack of sensitive and specific clinical tests to diagnose and monitor drug-induced injury of the kidney, liver and vascular system, which is a major hurdle in drug development.

The SAFE-T objective of qualifying new translational safety biomarkers is expected to enable potential new medicines to be evaluated more quickly and safely in patients. Daily care in clinical units should also benefit from this project, as these safety biomarkers are expected to support the patient’s treatment in order to prevent organ injuries on drug therapy.

The first year of this unique 5-year partnership of the European Pharmaceutical Industry, Academics and Small and Medium Enterprises was characterised by fruitful cooperation. At first, a generic scientific strategy was developed to define the qualification process of new translational safety biomarkers that will allow early identification, assessment, and management of drug-induced injuries throughout drug research and development. Common approaches and standard operating procedures were created which serve as a solid basis for next steps in assay development and biomarker qualification, and will ensure high common quality levels throughout all partner sites.

Furthermore, potential biomarker candidates for drug-induced injury of the kidney, liver and vascular system were evaluated and prioritized for clinical qualification. The chosen biomarkers require a variety of different assays for analysis. Thus, the initial step was to assess assay and reagent availability for the selected candidate biomarkers; assay development for the biomarker candidates (proteins, metabolites and RNA molecules) for translation studies has now been initiated.

As SAFE-T aims at providing statistically-based evaluations and evidence via integrative data analysis of each study for biomarkers qualification and linking the database with SAFE-T biobank sample repository, detailed requirements have been established for a project database and biobank in the first year. Standard operating procedures for sample handling and storage and all necessary documents for patient codification and correct sample tracking have been prepared.

Briefing documents for obtaining scientific advice from health authorities, such as European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), were prepared and submitted. The SAFE-T exploratory-phase plans of qualifying novel biomarkers for kidney and liver injuries were reviewed by, and discussed with EMA and FDA. The exploratory-phase plan for qualification of vascular injury biomarkers will be presented to the health authorities in October this year. EMA also contributes to the project as an external advisor. After the final stage of the project, the data will be submitted to the EMA, FDA and the Japanese PMDA agency who will be asked to issue a regulatory opinion regarding the qualification of the novel biomarkers for use in defined clinical contexts.

In summary, SAFE-T is working according to plan and has made considerable progress during the last 12 months. The main achievement during this year is the development of a productive collaboration between the partners from EFPIA, academia and SMEs that resulted in the planned project deliverables, such as lists of prioritised biomarkers for DIKI, DILI and DIVI, biomarker assays and defined biomarker qualification strategies.

SAFE-T has recently launched its website that gives more detailed information on the project http://imi-safe-t.eu
SAFE-T consortium members are:
- Almirall
- Amgen
- Argutus Medical Limited (formerly Biotrin)
- AstraZeneca
- Barcelona Cardiovascular Research Center
- Bayer Schering Pharma
- Boehringer Ingelheim
- Charité Hospital
- EDI GmbH
- Eli Lilly
- Firalis SAS
- GlaxoSmithKline
- Groupe Hospitalier Pitié Salpêtrière
- Hoffmann La Roche
- Interface Europe
- NMI Natural and Medical Sciences Institute at the University of Tuebingen
- Novartis Pharma
- Pfizer
- Sanofi-Aventis Research and Development
- Tel-Aviv (Souraski) Medical Center
For more information about SAFE-T, please contact:
Michael Merz, Coordinator of SAFE-T, (michael.merz@novartis.com)
Ina Schuppe Koistinen, Scientific Coordinator of SAFE-T (ina.schuppe-koistinen@astrazeneca.com)

Dr. Nadja Gugeler | idw
Further information:
http://imi-safe-t.eu

More articles from Life Sciences:

nachricht Plant escape from waterlogging
17.10.2017 | Christian-Albrechts-Universität zu Kiel

nachricht Study suggests oysters offer hot spot for reducing nutrient pollution
17.10.2017 | Virginia Institute of Marine Science

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Study suggests oysters offer hot spot for reducing nutrient pollution

17.10.2017 | Life Sciences

Breaking: the first light from two neutron stars merging

17.10.2017 | Physics and Astronomy

World first for reading digitally encoded synthetic molecules

17.10.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>